Imunon, Inc. (IMNN)
NASDAQ: IMNN · Real-Time Price · USD
0.5765
-0.0471 (-7.55%)
Jul 23, 2025, 10:49 AM - Market open

Company Description

Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines.

The company’s lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.

Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma.

In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; and PlaCCine for the coding of viral antigens that can elicit a strong immunological response.

The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022.

The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Imunon, Inc.
Imunon logo
CountryUnited States
Founded1982
IPO DateMar 5, 1985
IndustryBiotechnology
SectorHealthcare
Employees25
CEOStacy Lindborg

Contact Details

Address:
997 Lenox Drive, Suite 100
Lawrenceville, New Jersey 08648
United States
Phone609 896 9100
Websiteimunon.com

Stock Details

Ticker SymbolIMNN
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0000749647
ISIN NumberUS15117N6022
Employer ID52-1256615
SIC Code2834

Key Executives

NamePosition
Dr. Stacy R. Lindborg Ph.D.President, Chief Executive Officer and Director
Michael H. TardugnoExecutive Chairman
Dr. Khursheed Anwer M.B.A., Ph.D.Executive Vice President and Chief Scientific Officer
Kimberly GraperChief Financial Officer and Principal Financial and Accounting Officer
Timothy J. Tumminello CPAChief Accounting Officer and Controller
Susan Mary EylwardGeneral Counsel and Corporate Secretary
Kristin Longobardi M.B.A.Senior Vice President of Strategic Operations
Dr. Douglas V. Faller M.D., Ph.D.Chief Medical Officer

Latest SEC Filings

DateTypeTitle
Jul 22, 20258-KCurrent Report
Jul 22, 2025424B5Filing
Jul 14, 20258-KCurrent Report
Jul 11, 20258-KCurrent Report
Jun 13, 2025EFFECTNotice of Effectiveness
Jun 13, 20258-KCurrent Report
Jun 13, 2025424B3Prospectus
Jun 11, 2025ARSFiling
Jun 9, 2025DEF 14AOther definitive proxy statements
Jun 9, 20258-KCurrent Report